Navigating infectious complicatio...

Navigating infectious complications in cGVHD

Graft vs. Host Discussion by Graft vs. Host Discussion
S3 · E1
Sep 10, 2025
16:10

Episode notes

Chronic graft-versus-host disease (cGVHD) presents a spectrum of often hidden infectious challenges. When should a hematologist managing these complex patients call in an infectious disease specialist?

Our host, Dr. Gizelle Popradi, takes a deep dive into this topic with infectious disease expert Dr. Matthew Cheng, clinical researcher and assistant professor at the McGill University Health Centre.

In this episode, our experts explore critical considerations for managing infectious complications in patients with cGVHD, from identifying common and atypical infections to diagnostic pathways, and innovative prophylactic and therapeutic strategies. Discover practical insights that will enhance your approach to optimal care in this complex and vulnerable patient population.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Gizelle Popradi:

  • Direct financial relationship, including receipt of honoraria: AbbVie, Amgen, BMS, Daiichi Sankyo, Gilead, Incyte, Jazz, Kyowa Kirin, Mallinckrodt/Therakos, Medexus, Novartis, Paladin, Pfizer, Sanofi, Sean Gen, Servier, Sobi, Takeda.

Dr. Matthew Cheng:

  • Direct financial relationship, including receipt of honoraria: AstraZeneca, GEn1E Lifesciences, Merck, Nomic Bio, Pfizer, Takeda. Membership on advisory board or speakers' bureaus: GEn1E Lifesciences, Nomic Bio. Funded grants, research, or clinical trials: Canadian Institutes of Health Research, Fonds de Recherche du Québec – Santé, Amplyx Pharmaceuticals, Cidara Therapeutics, SCYNEXIS Inc. Patents on a drug, product, or device: Methods for detecting tissue damage, graft-versus-host disease, and infections using cell-free DNA profiling; methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA. All other investments or relationships: co-founder of Kanvas Biosciences.

MAT-CA-2500975

Keywords

cgvhd
hematology
transplant
Chronic graft-versus-host disease
infectious disease
infections
immunosuppression
prophylaxis
vaccination